Fig. 2: Associations of genetically proxied ACLY inhibition with the risk of cancer. | Communications Biology

Fig. 2: Associations of genetically proxied ACLY inhibition with the risk of cancer.

From: Genetic insights support PARP1 as a mediator in the protective association of ATP-citrate lyase inhibitors with melanoma

Fig. 2

A Primary analysis utilized the summary statistics of 17 cancers obtained from the UK Biobank and Genetic Epidemiology Research on Adult Health and Aging (GERA) cohorts. B Replication analysis utilized the summary statistics of 17 cancers from the FinnGen consortium (R9 version), the International Lung Cancer Consortium (ILCCO), the endometrial cancer association consortium (ECAC), and the deCODE genetic study. C Meta-analysis combined the ORs from primary analysis and replication analysis using fixed-effect model. OR [95% CI] represents the odds ratio for 17 common cancers per 1 SD decrease in blood ACLY expression. The dots represent OR from the two outcome datasets, while the diamonds represent OR from the combined dataset. I2 was used to measure the heterogeneity in the analysis. I2 values under 25% indicate mild heterogeneity, values over 50% suggest severe heterogeneity and between 25% and 50% the heterogeneity can be described as moderate.

Back to article page